13,078 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Bought by Sei Investments Co.

Sei Investments Co. bought a new stake in shares of Solid Biosciences Inc. (NASDAQ:SLDB) in the fourth quarter, Holdings Channel reports. The fund bought 13,078 shares of the company’s stock, valued at approximately $52,000.

Other hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Solid Biosciences in the 4th quarter valued at about $34,000. The Manufacturers Life Insurance Company acquired a new stake in Solid Biosciences during the third quarter worth about $71,000. XTX Topco Ltd purchased a new position in Solid Biosciences during the third quarter valued at approximately $121,000. Rhumbline Advisers lifted its holdings in Solid Biosciences by 10.5% in the fourth quarter. Rhumbline Advisers now owns 43,677 shares of the company’s stock valued at $175,000 after acquiring an additional 4,161 shares during the period. Finally, FMR LLC purchased a new stake in Solid Biosciences in the 3rd quarter worth approximately $305,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a report on Friday, March 7th. Truist Financial started coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright upped their price objective on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $15.67.

Solid Biosciences Stock Up 1.1 %

SLDB stock opened at $2.70 on Friday. Solid Biosciences Inc. has a 52 week low of $2.48 and a 52 week high of $10.99. The firm has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.78. The stock has a market capitalization of $209.23 million, a P/E ratio of -0.89 and a beta of 2.07.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.